词条 | Unapproved Drugs Initiative |
释义 |
It has been controversial due to the resulting increase in some drug prices. In April 2010, in an editorial in the New England Journal of Medicine (NEJM), A.S. Kesselheim and D.H. Solomon said that the rewards of this legislation are not calibrated to the quality or value of the information produced, that there is no evidence of meaningful improvement to public health, that it would be much less expensive for the FDA or National Institutes of Health to pay for trials themselves on widely available drugs such as colchicine, and that the cost burden falls primarily on patients or their insurers.[3] URL Pharma posted a detailed rebuttal of the NEJM editorial.[4] Drugs affected
References1. ^{{cite web |url=http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm118990.htm |title=Unapproved Drugs Initiative (fda.gov)}} {{drug-stub}}2. ^1 {{cite web |url=http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm238675.htm |title=Enforcement Actions by Drug Class }} 3. ^{{cite journal |author=Kesselheim AS, Solomon DH |title=Incentives for drug development--the curious case of colchicine |journal=N. Engl. J. Med. |volume=362 |issue=22 |pages=2045–7 |date=June 2010 |pmid=20393164 |doi=10.1056/NEJMp1003126 |url=http://content.nejm.org/cgi/content/short/362/22/2045}} 4. ^Response from URL Pharma 1 : Food and Drug Administration |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。